Company: MDCXW
Filing Date: 2025-11-17
Form Type: 424B3
Source: 0001062993-25-016876
Chunk: 3

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-17
Form: 424B3
Chunk 3
---
 |
|:--------------------------------------------------------------------------------------------------------------|--------------:|:--|-----------:|:----|:--------------------|:----|:--|:-------|:----|:--|-----------:|:----|:--|:------------|:--|:--|:--------------|:----|:--|:------------|:----|:--|-----------:|:--|
| Balance as of December 31, 2024                                                                               |    11,816,721 | $ | 30,518,195 |     | -                   |     | $ |        |     | $ |  1,520,412 |     | $ | (28,903,903 | ) | $ |               |     | $ |             |     | $ |  3,134,704 |   |
| Issuance of common shares and warrants in connection with Regulation A, net of issuance costs of $483,020     |     1,490,000 |   |  2,076,507 |     | -                   |     |   | -      |     |   |  1,612,474 |     |   | -           |   |   | -             |     |   | -           |     |   |  3,688,981 |   |
| Issuance of common shares in connection with SEPA offering costs                                              |       105,840 |   |    300,000 |     | -                   |     |   | -      |     |   |          - |     |   | -           |   |   | -             |     |   | -           |     |   |    300,000 |   |
| Issuance of common shares upon exercise of stock warrants                                                     |         5,000 |   |     14,000 |     | -                   |     |   | -      |     |   |          - |     |   | -           |   |   | -             |     |   | -           |     |   |     14,000 |   |
| Share-based compensation                                                                                      |             - |   |          - |     | -                   |     |   | -      |     |   |    112,277 |     |   | -           |   |   | -             |     |   | -           |     |   |    112,277 |   |
| Net loss and comprehensive loss for the period